Ebola, known medically as Ebola virus disease, is a rare but severe illness that can cause a dangerous, sometimes fatal fever with bleeding complications. First identified in 1976, it spreads through direct contact with the body fluids of an infected person and has caused a series of outbreaks in parts of Africa, including a large 2026 outbreak that drew global attention. Ebola is frightening because it can be deadly and moves quickly, but it is not airborne, it does not spread before symptoms appear, and there are now an approved vaccine and approved treatments for one of its most dangerous forms. This guide explains what Ebola is, the symptoms and how they progress, how it spreads and is diagnosed, the treatments and vaccine available, recent outbreaks, and the latest research.
What is Ebola?
Ebola virus disease is a type of viral hemorrhagic fever, meaning a viral infection that can damage blood vessels and, in some cases, cause bleeding. It is caused by a group of viruses called ebolaviruses, part of the filovirus family. Fruit bats are believed to be the natural host, and the virus usually enters the human population when someone has contact with an infected animal, after which it can spread from person to person.
Several distinct species of ebolavirus can make people sick, and they differ in severity and in whether specific treatments exist, as shown below. Historically, Ebola outbreaks have had case fatality rates ranging widely from about 25 percent to 90 percent, averaging around 50 percent, though early and aggressive supportive care substantially improves the odds of survival.
| Ebolavirus species | Notes |
|---|---|
| Ebola virus (Zaire) | Historically the most common and deadly; the only species with an approved vaccine and approved treatments |
| Sudan virus | Causes recurring outbreaks; no vaccine or drug is specifically approved for it |
| Bundibugyo virus | Behind the large 2026 outbreak; no species-specific approved countermeasures |
| Taï Forest virus | Very rare in humans |
Symptoms of Ebola
Symptoms usually appear 2 to 21 days after exposure, most often around 8 to 10 days, and a person is not contagious until symptoms begin. Illness typically starts with what clinicians call dry symptoms and then progresses to wet symptoms as it worsens.
| Phase | Typical symptoms |
|---|---|
| Early (“dry”) | Sudden fever, severe fatigue, muscle and body aches, headache, and sore throat |
| Later (“wet”) | Vomiting, severe watery diarrhea, abdominal pain, and sometimes a rash |
| Severe | Dehydration, organ problems, and, in some cases, unexplained bleeding or bruising |
Contrary to popular belief, dramatic bleeding is not the most common feature. Unexplained bleeding or bruising appears in a minority of cases and is more typical of severe or fatal illness. The greatest dangers early on are actually fluid loss from vomiting and diarrhea and the resulting shock, which is why prompt fluid and electrolyte support is so important.
How Ebola spreads and what causes it
Ebola spreads through direct contact with blood or body fluids, such as vomit, diarrhea, urine, sweat, saliva, semen, or breast milk, from a person who is sick with or has died from the disease, or through contact with contaminated objects like needles and bedding. Caring for a sick family member and preparing a body for burial are common routes of spread, which is why outbreaks often move through households and healthcare settings without strict precautions.
Importantly, Ebola is not spread through the air like the flu or COVID-19, and it does not spread from a person who has no symptoms. The virus can linger in certain protected parts of the body after recovery, including the eyes, testes, and nervous system, which allows rare transmission through semen months after a survivor recovers. Understanding these specific routes is what makes Ebola controllable through careful infection prevention.
How Ebola is diagnosed
Because early Ebola looks like many common tropical illnesses, laboratory testing is essential to confirm it. The standard test is a molecular test called RT-PCR, which detects the virus’s genetic material in a blood sample around the time fever begins; antigen and antibody tests can supplement it, especially later in the illness. Testing is done under strict safety precautions in specialized laboratories.
Blood work in Ebola often shows a characteristic pattern that helps guide care. The platelet count tends to fall, liver enzymes rise sharply with a typical pattern, and clotting can become impaired. Reviewing the platelet count on a blood test and the AST liver enzyme and its normal range shows why clinicians watch these values closely, since a dropping platelet count and climbing liver enzymes signal that the infection is stressing multiple organ systems. Learning how to read the flags and reference ranges on a lab report makes these patterns easier to follow.
Treatment options for Ebola
Two pillars of care define modern Ebola treatment: aggressive supportive care for everyone, and targeted antibody drugs for the Zaire species. Supportive care means replacing lost fluids and electrolytes, maintaining blood pressure and oxygen, and treating other infections and complications as they arise. This basic care alone meaningfully improves survival and is the foundation of every outbreak response.
For disease caused by the Zaire species of Ebola virus, two monoclonal antibody treatments are approved in the United States and can substantially improve survival when given early. These laboratory-made antibodies bind the virus and help the immune system clear it. A crucial gap remains, however: there is no treatment specifically approved for the Sudan or Bundibugyo species, so care for those infections relies on supportive treatment and, at times, investigational therapies used during outbreaks. People severely ill with Ebola can deteriorate into shock and multi-organ failure, a process that overlaps with the body-wide response described in sepsis, which is why intensive supportive care matters so much.
Preventing Ebola
Prevention combines vaccination, infection control, and safe practices around survivors. An approved vaccine protects against the Zaire species and is used to shield health workers and the contacts of cases during outbreaks, a strategy that has helped bring several outbreaks under control. As with treatment, though, the vaccine is specific to the Zaire species and is not expected to protect against the Sudan or Bundibugyo viruses.
During outbreaks, the most effective measures are avoiding contact with the blood and body fluids of sick or deceased people, using protective equipment and safe burial practices, isolating and caring for patients in dedicated facilities, and monitoring contacts for symptoms. For travelers, the everyday risk is very low, and simple precautions in affected regions are usually enough. Survivors receive counseling about the small risk of lingering virus in body fluids and how to prevent onward transmission.
Recent outbreaks and long-term effects
Ebola continues to cause periodic outbreaks. In 2026, an outbreak caused by the Bundibugyo species in the Democratic Republic of the Congo and Uganda was declared a public health emergency of international concern by the World Health Organization and grew into one of the largest Ebola outbreaks recorded, underscoring the gap in species-specific vaccines and drugs. A smaller Sudan virus outbreak in Uganda in early 2025 was contained after a single confirmed case. Survivors, meanwhile, can face what is sometimes called post-Ebola syndrome, with lingering problems such as joint pain, eye inflammation, fatigue, and neurological or memory difficulties that may persist for years.
Latest scientific advances in Ebola research
Recent research highlights both progress and the work still ahead, especially for the species without approved countermeasures. According to PubMed-indexed research, a 2026 review in The Lancet Global Health analyzed every known Sudan virus outbreak and found a pooled case fatality rate of about 49 percent that fell to 29 percent in the 2025 Uganda outbreak, crediting improved supportive care, while noting that survivors can retain protective immunity for many years (Whitworth et al., 2026). What this means for you: better basic hospital care is saving lives even where no specific drug exists, which is why early treatment matters so much.
A 2026 review in the New England Journal of Medicine on the Bundibugyo outbreak explained that no vaccine or therapy is specifically licensed for that species, but that antibody and vaccine tools built against the Zaire species may offer partial cross-protection and are being used experimentally (Sullivan, 2026). What this means for you: responders can still deploy existing tools against a new strain, though species-matched countermeasures are urgently needed. A separate 2026 study in JAMA Neurology followed Ebola survivors in Liberia for more than seven years and found significantly higher rates of persistent memory loss, irritability, and trouble concentrating compared with people who were never infected (Billioux et al., 2026). What this means for you: surviving Ebola is only the first step, and long-term follow-up care for neurological and other lingering effects is an important part of recovery.
Glossary of key Ebola terms
| Term | Definition |
|---|---|
| Viral hemorrhagic fever | A viral illness that can damage blood vessels and cause bleeding. |
| Filovirus | The family of viruses that includes ebolaviruses and Marburg virus. |
| Zaire ebolavirus | The species with an approved vaccine and approved antibody treatments. |
| Reservoir host | An animal, likely fruit bats, that carries the virus in nature. |
| RT-PCR | A molecular test that detects the virus’s genetic material in blood. |
| Monoclonal antibody | A lab-made antibody used as a targeted treatment against the virus. |
| Post-Ebola syndrome | Lingering symptoms such as joint pain, eye problems, and fatigue in survivors. |
Frequently asked questions about Ebola
Is Ebola airborne?
No. Ebola is not spread through the air. It spreads through direct contact with the blood or body fluids of a person who is sick with or has died from the disease, or through contaminated objects. This is a key difference from respiratory viruses like the flu.
How do you catch Ebola?
People catch Ebola through direct contact with infected body fluids, including blood, vomit, diarrhea, sweat, saliva, semen, and breast milk, or with contaminated objects such as needles. It can also spread from infected animals to people. A person is not contagious until they have symptoms.
What are the first signs and symptoms of Ebola?
Early symptoms include a sudden fever, severe fatigue, muscle aches, headache, and sore throat. These are followed by vomiting, diarrhea, and abdominal pain, and in some cases a rash or unexplained bleeding. Symptoms usually begin 2 to 21 days after exposure.
Is there a cure or treatment for Ebola?
There is no simple cure, but treatment has improved greatly. Everyone benefits from supportive care such as fluids and electrolyte replacement, and two approved antibody drugs can substantially improve survival for disease caused by the Zaire species. No drug is specifically approved yet for the Sudan or Bundibugyo species.
Is there an Ebola vaccine?
Yes, an approved vaccine protects against the Zaire species of Ebola virus and is used to protect health workers and the contacts of cases during outbreaks. It is not expected to protect against the Sudan or Bundibugyo species, for which vaccines are still in development.
How deadly is Ebola?
Ebola can be very deadly, with historical case fatality rates ranging from about 25 percent to 90 percent and averaging around 50 percent. However, early and aggressive supportive care, along with approved treatments for the Zaire species, has lowered death rates considerably in recent outbreaks.
Sources
- Centers for Disease Control and Prevention — About Ebola — CDC, 2024 — cdc.gov
- World Health Organization — Ebola Disease — WHO Fact Sheet, 2025 — who.int
- U.S. Food and Drug Administration — Ebola Preparedness and Response — FDA, 2024 — fda.gov
- Whitworth HS, et al. — Sudan virus disease in humans — The Lancet Global Health, 2026 — doi.org/10.1016/S2214-109X(26)00072-0
- Sullivan NJ — Bundibugyo Virus Disease in 2026: Clinical and Public Health Responses — New England Journal of Medicine, 2026 — doi.org/10.1056/NEJMra2607216
- Billioux BJ, et al. — Neurological Manifestations in Adult Survivors of Ebola Virus Disease — JAMA Neurology, 2026 — doi.org/10.1001/jamaneurol.2026.2112
Further reading
- See why a falling platelet count matters in serious infections in this guide to the platelet count on a blood test.
- Understand the liver enzyme that rises in Ebola in this guide to the AST test and its normal range.
- Learn how a severe infection can overwhelm the body in this guide to the life-threatening response of sepsis.
- Compare Ebola with another mosquito-borne viral fever in this guide to the symptoms and warning signs of dengue fever.
- Build confidence reading test results with this guide to reference ranges, flags, and next steps on a lab report.
Understand your lab results with BloodSense
Ebola shows how much a blood panel can reveal about a serious infection, from a falling platelet count to sharply rising liver enzymes and clotting changes that track how hard the body is being hit. Whenever you receive lab results, seeing where each value falls against its reference range, and how the numbers move together, makes them far easier to understand. BloodSense translates a full lab report into plain language, showing what each marker means and helping you follow changes over time rather than reading one line in isolation.
